Neurocrine sheds 200 Indiplon reps

Share this article:
Neurocrine Biosciences has laid off its entire 200-person sales force, the San Diego firm said. The decision follows Pfizer's ending of its marketing partnership with Neurocrine after the latter lost approval for insomnia drug Indiplon, and Pfizer lost US patent protection for Zoloft.

Neurocrine was then unable to acquire a product to keep the reps busy as it continues to seek FDA approval for Indiplon.

Neurocrine plans to meet with the FDA to finalize plans for the resubmission of each Indiplon NDA and to commercialize Indiplon quickly upon approval.
Neurocrine also said it is reviewing other possible future partnerships.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Pharmaceutical


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.